Cargando…

Interleukin-6 Blockade With Tocilizumab in Anakinra-Refractory Febrile Infection-Related Epilepsy Syndrome (FIRES)

Febrile infection-related epilepsy syndrome (FIRES) is characterized by new onset refractory status epilepticus in a previously healthy child that is associated with poor cognitive outcomes and chronic epilepsy. Innate immune system dysfunction is hypothesized to be a key etiologic contributor, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stredny, Coral M., Case, Siobhan, Sansevere, Arnold J., Son, MaryBeth, Henderson, Lauren, Gorman, Mark P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745547/ https://www.ncbi.nlm.nih.gov/pubmed/33403221 http://dx.doi.org/10.1177/2329048X20979253

Ejemplares similares

Long-term neuropsychological outcomes in children with febrile infection-related epilepsy syndrome (FIRES) treated with anakinra
por: Shrestha, Anima, et al.
Publicado: (2023)

Anakinra usage in febrile infection related epilepsy syndrome: an international cohort
por: Lai, Yi‐Chen, et al.
Publicado: (2020)

Proposal to optimize evaluation and treatment of Febrile infection‐related epilepsy syndrome (FIRES): A Report from FIRES workshop
por: Koh, Sookyong, et al.
Publicado: (2021)

Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection–related epilepsy syndrome
por: Dilena, Robertino, et al.
Publicado: (2019)

Sevoflurane as bridge therapy for plasma exchange and Anakinra in febrile infection–related epilepsy syndrome
por: L’Erario, Manuela, et al.
Publicado: (2021)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
por: de la Calle, Cristina, et al.
Publicado: (2021)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Anakinra/tocilizumab: Primary biliary cholangitis: case report
Publicado: (2021)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Posterior-onset Rasmussen's encephalitis with ipsilateral cerebellar atrophy and uveitis resistant to rituximab
por: Sansevere, Arnold J., et al.
Publicado: (2020)

International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection‐related epilepsy syndrome (FIRES): Summary and clinical tools
por: Wickström, Ronny, et al.
Publicado: (2022)

Hippocampal Changes in Febrile Infection-Related Epilepsy Syndrome (FIRES)
por: Agarwal, Amit, et al.
Publicado: (2015)

Claustrum sign in febrile infection-related epilepsy syndrome (FIRES)
por: Guo, Kundian, et al.
Publicado: (2023)

The Claustrum Sign in Febrile Infection-Related Epilepsy Syndrome (FIRES)
por: Di Dier, Kelly, et al.
Publicado: (2023)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
por: Mahamid, Mahmud, et al.
Publicado: (2011)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Comparison of Anakinra and Tocilizumab in Anticytokine Therapy in the Treatment of Coronavirus Disease-2019
por: Ozkan, Feyza, et al.
Publicado: (2022)

Refractory Sweet Syndrome Treated with Anakinra
por: Shahid, Zainab, et al.
Publicado: (2019)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Towards a Treatment for Neuroinflammation in Epilepsy: Interleukin-1 Receptor Antagonist, Anakinra, as a Potential Treatment in Intractable Epilepsy
por: Yamanaka, Gaku, et al.
Publicado: (2021)

Cannabidiol in the acute phase of febrile infection‐related epilepsy syndrome (FIRES)
por: Fetta, Anna, et al.
Publicado: (2023)

Tocilizumab versus anakinra in COVID-19: results from propensity score matching
por: Arcani, Robin, et al.
Publicado: (2023)

Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
por: Del Buono, Marco Giuseppe, et al.
Publicado: (2022)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2023)

Anakinra treatment for refractory cerebral autoinflammatory responses
por: Jang, Yoonhyuk, et al.
Publicado: (2022)

Febrile infection-related epilepsy syndrome (FIRES): prevalence, impact and management strategies
por: Serino, Domenico, et al.
Publicado: (2019)

Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study
por: KÜÇÜKŞAHİN, Orhan, et al.
Publicado: (2022)

Infantile Hemiconvulsion-Hemiplegia and Epilepsy (IHHE) in a boy with tuberous sclerosis complex
por: Moschopoulos, Chariton, et al.
Publicado: (2021)

Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?
por: Kow, C.S., et al.
Publicado: (2021)

Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors
por: Cure, Erkan, et al.
Publicado: (2021)

Systemic inflammatory markers and EEG features of children with FIRES receiving anakinra
por: Lai, Yi‐Chen, et al.
Publicado: (2023)

Diminished toll-like receptor response in febrile infection-related epilepsy syndrome (FIRES)
por: Hsieh, Meng-Ying, et al.
Publicado: (2020)

Long-term outcomes of adult cryptogenic febrile infection–related epilepsy syndrome (FIRES)
por: Shi, Xiaojing, et al.
Publicado: (2023)

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2019)

Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
por: Di Nisio, Marcello, et al.
Publicado: (2021)

How to Help Your Patients Enroll in the New-Onset Refractory Status Epilepticus (NORSE) and Febrile Infection-Related Epilepsy Syndrome (FIRES) Family Registry, and Other Rare Epilepsy Registries
por: Kazazian, Karnig, et al.
Publicado: (2021)

Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Bhat, Chandrika S., et al.
Publicado: (2021)

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities
por: Diorio, Caroline, et al.
Publicado: (2022)

Anti-interleukin-6 receptor therapy with tocilizumab for refractory pseudophakic cystoid macular edema
por: Pham, Brandon Huy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mudmglfgpjjfkoqasnrkl23u8s